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The standards of the Canadian Association of Radiologists
(CAR) are not rules but are guidelines that attempt to define
principles of practice that should generally produce radio-
logic care. The physician and the medical physicist may
modify an existing standard as determined by the individual
patient and available resources. Adherence to CAR standards
will not assure a successful outcome in every situation. The
standards should not be deemed inclusive of all proper
methods of care or exclusive of other methods of care
reasonably directed to obtaining the same results. The
standards are not intended to establish a legal standard of care
or conduct, and deviation from a standard does not, in and of
itself, indicate or imply that such medical practice is below an
acceptable level of care. The ultimate judgement regarding
the propriety of any specific procedure or course of conduct
must be made by the physician and medical physicist in light
of all circumstances presented by the individual situation.
Introduction
Bone mineral density (BMD) testing by central dual-energy
x-ray absorptiometry (DXA) is the fundamental technology
for the diagnosis, treatment, and monitoring of osteoporosis,All appendices cited in this article are available via the CARJ website at
www.carjonline.org.
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bone diseases [1e21]. In 2005, CAR, in conjunction with the
Scientific Advisory Council of Osteoporosis Canada, issued
a set of guidelines for the reporting of BMD test results [1].
That document set down some of the principles to be used in
performing BMD and the recommended content of bone
mineral densitometry reports. It also established, for the first
time, a methodology for determining absolute fracture risk for
individuals 50 years of age and older. Subsequent population
studies have demonstrated the performance of the risk system
in the Canadian population [22,23]. The intention of the CAR
was to periodically update the BMD document to clarify points
and to adapt to evolving data and approaches in the fields of
osteoporosis and metabolic bone disease. The CAR BMD
guidelines are issued here as technical standards and represent
the current expectations for BMD testing and reporting in
Canada. These standards must be met to be accredited by the
CAR BMD Accreditation Program. This document is not
intended to serve as a primer on bone densitometry and, for the
most part, describes standards that must be met to achieve
CAR BMD accreditation [24e26]. In some instances in which
there is not yet consensus on the optimal approach, suggestions
or options are provided, anticipating that those aspects will be
discretely defined in the future versions of CAR Technical
Standards for Bone Mineral Densitometry Reporting.Information That Should Be Provided by Referring
Physicians
BMD consultation requests should include patient
demographics, the indication for BMD testing, factors ofll rights reserved.
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surgery, or bone disease in scan regions), osteoporosis
medication history, factors of relevance to fracture-risk
determination in patients 50 years of age or older (fragility
fracture history, glucocorticoid history), and any other
pertinent medical information [1,2,9,18,19,27e34]. On
follow-up scans done on patients who receive osteoporosis
drug therapy, it is particularly helpful if BMD requests
indicate the scan year of primary interest for comparison,
with details of current osteoporosis drug therapy and
duration [1,2,11,19,35,36]. Although this level of informa-
tion is often not provided, a thorough patient history from the
referring physician is to be encouraged [1,19,28].
Adult Patient Questionnaire
A template questionnaire that acquires the appropriate
information necessary for BMD testing in adults (defined as
those 18 years of age or older) is presented in Appendix e1
(available online at www.carjonline.org), modified from the
2005 guidelines [1,19,28,37,38]. This questionnaire can
either be filled in by patients and then clarified by trained
facility staff, or a history can be directly taken by facility
staff. The specific items on the questionnaire are intended to
collect the minimum information needed to analyse a BMD
scan and to determine absolute fracture risk in those 50 years
or older [1,14,27]. Additional history items that are of rele-
vance to individual patients should also be collected, such as
menopausal history, medication history, and illnesses
[1,2,9,15,18,19,30,32e34,37].
BMD Report Contents
Report contents will differ, depending on whether it is an
adult (age 18 years or older) or pediatric study, and whether
it is a first-time or follow-up study.Components of a First-time Adult BMD ReportThe components of a first-time adult BMD report are
shown in Appendix e2 [1,18,38,39].
Demographics
Demographics should include patient name, date of birth,
sex, provincial health care number or other identifier, height,
weight, scan date, report date, name of the referring
physician, name of the reporting physician, and BMD facility
name and location [1,18,38e40]. Weight and height should
be measured at the BMD facility [41,42]. Neither values
reported by the patient nor measurements provided by other
medical practitioners should be used, other than in
exceptional circumstances in which it is not possible to carry
out the measurements (such as if the patient cannot stand). If
height or weight data were not measured directly by the
BMD facility, then this should be indicated in the report.Weight can be measured with either a mechanical or
electronic scale that is medical grade [41]. Facilities are
encouraged to use wall-mounted height-measuring devices,
referred to as stadiometers, that use standardized positioning
of patients [18,41e44]. It is also encouraged that 3 height
measurements be made, with repositioning between each
measurement, and the average used as the height value. The
reason for this is that, just as with bone density quantitation,
height measurements have significant precision error and this
is minimized by averaging several assessments [41e44]. At
the current time, this height measurement methodology is
a recommendation and is not a requirement for accreditation.Diagnostic Category
The current standard for reporting the diagnostic category is
shown in Appendix e3 [1,14,15,40]. The diagnostic category is
based on the lowest T-score for an individual from the results
for the lumbar spine, total hip, trochanter, and femoral neck
[1,14,45]. If the forearm is measured, then the value for the
third or 33% site is used [1,14,18,45,46]. If a total body scan is
done, then the total body BMD T-score may be used [1,14]. A
change has been made from the 2005 CAR BMD Clinical
Practice Guidelines for diagnostic categories in women [1,14].
Whereas categorization in women was previously based on
a combination of menopausal status and age, the current
standard is based only on age, with different terminology for
women younger than 50 years old and those 50 years and older
[1]. The intent is to make the categorization coherent with
absolute fracture-risk determination methodology, which does
not consider menopausal status [1].Fracture-risk Category
The absolute fracture-risk category should be reported for
men and women 50 years of age and older [1,14,27] when
relevant history is available. The current standard for
determining absolute fracture risk is the method described in
the 2005 CAR Clinical Practice Guidelines [1,14]. This risk
determination incorporates age, BMD results, sex, fragility
fracture history, and glucocorticoid history. Bone-active drug
therapy will alter fracture risk if the drug is taken regularly, if
it is taken correctly, and if it is achieving the desired effects
[47e52]. If a patient who undergoes BMD testing for the
first time is already on bone-active drug therapy, then the
fracture-risk category should be provided, but a statement
should be included that indicates that the risk may be
lower than calculated if osteoporosis drug therapy is effective
[47e52]. For individuals younger than 50 years old, absolute
risk assessment is not available, and a fracture-risk category
should not be reported. The World Health Organization’s
10-year fracture-risk calculation system, called FRAX
[53,54], may be included in some DXA software. This,
however, is a country-specific risk calculator, and there is no
validated Canadian FRAX model. FRAX is not to be used for
determining fracture risk [53,54].
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For individuals 50 years of age or older, the report should
state the specific history used in risk determination when either
the fragility fracture status or a glucocorticoid history is
positive [1e3,9,13,14,18,29e31]. This transparency allows
the referring physician to understand how the fracture risk was
arrived at and allows the referring physician to provide
clarification or additional information if appropriate. The
absolute fracture-risk categories were originally derived by
using data from 4 types of fractures: forearm, vertebra,
proximal femur, and proximal humerus [1e3,9,53,54].
Fractures at these sites should generally be regarded as
fragility fractures if they occur subsequent to a fall from
standing or sitting heights. Other types of fractures have
weaker relationships to osteoporosis but may be regarded as
fragility fractures if the history suggests that the fracture
occurred with a degree of trauma that would not normally be
expected to lead to a broken bone [2,3,9,22,55]. Only fractures
that occurred after age 40 years should be considered in
determining risk [1,2,56].
Glucocorticoid history is considered positive if predni-
sone (or other glucocorticoids in terms of prednisone
equivalents) was in use at a dose greater than 7.5 mg per day
for more than 3 months in the prior 12 months (meaning for
more than 90 total days of the preceding 365 days, not
necessarily consecutive). This is a clarification of the 2005
CAR Clinical Practice Guidelines [1,30,31,57].BMD Data
Care must be taken in all technical aspects of how
scanning is performed, including adherence to manufacturer
protocols, proper positioning, subregion assignment, bone
tracing, determination of regions of interest, and quality
assurance [18,19,40,58e67]. A minimum of 2 skeletal sites
should be scanned and reported [1,15,18,19,63,67e69]. The
usual sites would be the lumbar spine and the proximal
femur [1,15,18,19,40,45,63,69]. When analysing the lumbar
spine, L1-L4 should be used unless the decision is made to
exclude 1 or 2 vertebrae because of technical artifacts
[1,45,63]. A minimum of 2 vertebrae should be used. Inter-
pretation should not be based on a single vertebra
[1,45,70,71]. If a report includes graphical representation of
results, then the graph must present data and reference curves
for the vertebrae actually used in interpretation [1].
Consideration can be given to excluding a particular vertebra
if the T-score of that vertebra is more than 1 standard
deviation greater than the T-score of the vertebra with the
next highest value [1,63,72]. It is not mandatory that a high-
density vertebra be excluded, but it should be evaluated for
causes of artifact and a decision made as to whether it should
be retained in the vertebral analysis.
For the proximal femur, the left side should be measured
unless it is not available or is invalid, or if the right hip was
previously measured [73,74]. Results should be reported forthe total hip, femoral neck, and trochanteric region
[1,14,45,67,69,75]. If either the spine or hip site is not
available or invalid because of artifact, then another site
should be substituted [1,14,18,19]. The nondominant
forearm is the site of choice, and the midshaft of the radius
(referred to as the one-third radius or 33% radius) should be
reported [1,15,18,19,67]. If the nondominant forearm is not
available or is invalid, then the dominant side may be used. If
the wrist cannot be measured, then total body BMD can be
assessed [1,19]. The head may be included or excluded when
analysing the scan. If the head is excluded, then this should
be noted in the report. If the spine cannot be measured, and
neither forearm nor total body measurements are available,
then bilateral hip measurements may be made [18,19,73].
The 2 hip measurements should be reported separately, not as
an averaged value [18,73,74]. For patients whose weight
exceeds the limit of the DXA equipment, bilateral forearm
studies may be done unless 1 side is not available or is
invalid [18].
For each skeletal site with a valid scan, reported density
results should include absolute BMD (in g/cm2 to 3 decimal
places) and T-score (to 1 decimal place) [1,18,27,75].
T-scores should be derived by using the manufacturer’s white
female reference population database for women and the
white male database for men [1,14,18,22,23]. Non-white
reference databases should not be used. The reference
database and version should be specified in the report [19].
Limitations
Any structural abnormalities, anatomical variants, arti-
facts, suboptimal positioning, or other issues that impact scan
reliability and interpretation need to be considered when
interpreting BMD results [1,18,19,27,58,61,65,66,70,76e88].
A judgement needs to be made as to whether they render
results invalid or impact on the interpretation. Some sources
of artifact (such as metal on clothes or in pockets, or recent
barium or nuclear medicine studies) are preventable, and care
should be taken to assess for these before scanning and either
remove the source of artifact or postpone the scan to a future
date [11,40,63,65,81,87,89,90]. Sources of artifact relevant to
the scan should be noted in the report.
Skeletal size can affect BMD readings, with larger bones
producing falsely high values and smaller bones producing
falsely low values [91e94]. There is no accepted means of
correcting for skeletal size, but height or weight outside the
normal range should be noted and should be considered in
the interpretation of results. Some manufacturer databases do
not provide T-scores between the ages of 18e20 years. It is
acceptable in this circumstance to provide Z-scores and to
use the pediatric approach to reporting. This should be noted
in the report.
Interpretation
A narrative section on interpretation and implications of
BMD results should be provided. This narrative should not
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considerations can be provided within the context of
Osteoporosis Canada Guidelines to the degree appropriate
to the knowledge and experience of the reporting physician
[2].
Recommended Follow-up Date
A recommendation should be included for the timing of the
next DXA study [1,18,19,27]. Published Canadian Osteopo-
rosis and BMD Guidelines provide some direction but do not
cover all clinical scenarios. The timing of serial testing should
be driven by the expected rate of bone loss. The intention of
serial monitoring is to provide a sufficient period of time for
anticipated changes in density to exceed the precision error of
the DXA method, which also renders a stable density
informative [2,4,15,18e20,35,47e52,63e65]. A guide based
on published recommendations but encompassing a wider
range of clinical situations is provided in Appendix e4. When
indicating recommended timing of the subsequent BMD test,
consideration should be given to specifying the year of
recommended follow-up rather than a time interval, because
this makes the report more readily implementable by referring
physicians. For follow-up periods of less than 2 years, the
month of recommended follow-up could also be included. This
approach is not a requirement for accreditation at this time.
Definitions
Any terminology or abbreviations used in the report
should be defined. Some examples are the following:
 T-score: the number of standard deviations above (þ) or
below (e) the mean peak density.
 Fracture risk: high fracture risk is a 10-year absolute
fracture risk >20%; moderate fracture risk is a 10-year
absolute fracture risk in the range of 10%e20%; low
fracture risk is a 10-year absolute fracture risk <10%.
 TBLH: total body less head, assessment of the entire
body minus the head region.Machine Identification
Machine identification should include DXA brand, model,
and serial number.Components of a Follow-up Adult BMD ReportThe components of a follow-up adult BMD report are
shown in Appendix e5. A follow-up adult BMD report
should include all of the components of a first-time adult
report. In addition, items specific to follow-up also need to be
described, including changes in density, statistical parame-
ters that relate to measurement error, aspects of interpretation
that relate density changes to the clinical situation, and
definitions relevant to follow-up.Demographics
Change in height as measured at the BMD facility should
be noted [18,42,43]. In particular, height loss that exceeds 2
cm over 3 years or less should be emphasized, because this
amount of height change has been shown to have a high
predictive value for incident vertebral fractures that
developed during the monitoring period [18,43]. A change in
weight should also be noted, because this can create
artifactual changes in BMD values [95,96]. There is no
consensus as to what the threshold should be for flagging
a change in weight as being of potential importance as
a source of artifact, with some physicians using percentage
change in weight and others using absolute change in weight.
A suggested threshold is a 10% change in weight over the
time period of monitoring. The use of this weight-change
threshold is only a recommendation and is not a require-
ment for accreditation. Each reporting physician, however,
must define a weight change threshold and use it in all serial
reporting by applying it to each pair of BMD measurements
for which change in BMD is reported.
Fracture-risk Category
The absolute fracture-risk category should be reported for
women 50 years of age and older, and for men 50 years and
older, regardless of therapy that may be in use [1,14,27]. If
bone-active drug therapy is in use, then the fracture-risk
category should be provided, but a statement should be
included that indicates that the risk may be lower than
calculated if osteoporosis drug therapy is effective
[1,2,15,47e52].
Changes in Density
When comparing serial assessment, the same machine
should be used when possible [1,15,63], and positioning and
subregion assignment must be consistent [40,59e61,63]. The
same reference population database should be used for serial
studies when possible [15]. If the reference database must be
changed, then this should be noted in the report. The
description of density change should include the absolute
density change (in g/cm2, to 3 decimal places) and
percentage change (to 1 decimal place) [18,27]. The
percentage change must be derived by using absolute density,
not T-scores [40]. An annualized rate of change may be
reported, but this is optional. The skeletal sites for which
changes in density are to be reported are the lumbar spine (by
using whichever vertebrae are considered valid, with
a minimum of 2 vertebrae) and the total proximal femur
[1,14,18]. Hip subregions should not be used [15,40]. If
either the spine or hip is not available, it is permissible to
report changes at a single site. If the forearm or total body
BMD is being monitored in lieu of the spine or hip, then
change can be reported for the one-third or 33% proximal
radius or for the total body BMD [15,63]. It must be
recognized that the change profile at these sites may not
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as well with drug responses [15,63]. This will need to be
addressed in the interpretation section.
Changes in density must be reported in relation to (1) the
first study on file; (2) the most recent previous study; and
(3) the study done closest to the initiation of the current
clinical treatment regimen (if any), if this can be ascertained
[37]. The latter BMD change is the one of greatest impor-
tance for patients on drug therapy, and also relevant to
patients who started lifestyle and nutritional supplements for
bone health [15,35,36,40,47e52,95,97e102]. Ideally, the
comparison study of primary interest should be indicated on
the requisition by the referring physician, but, if it is not
provided, then the reporting physician is responsible for
obtaining this information by patient history.
Statistical significance must be reported for each BMD
skeletal-site comparison and indicate whether the difference is
considered significant at a 95% level of confidence
[1,4,5,18,61,103e108]. The manufacturer’s software deter-
mination of statistical significance is not to be used [1,18,61].
Each facility must determine precision error for each DXA
machine and for each skeletal site (including forearm and total
body if these sites are measured by the facility and are used for
serial monitoring) by using the least significant change (LSC)
methodology and use this value when determining statistical
significance [1,4,5,18,61,105e108]. It is permissible to apply
results derived from precision testing on 1 side (forearm or hip)
to serial scans done by using the opposite side of the body. A
worksheet for determining precision error and LSC is available
on the CAR Web site (www.car.ca). A follow-up BMD report
should state the LSC in absolute values (g/cm2, to 3 decimal
places) for each skeletal site for which change is reported
[1,14,18,27]. Whenever possible, the same instrument should
be used for serial studies on an individual patient [1,15,63].
Comparisons between measurements done on different
machines can be made only if intermachine precision between
the 2 devices has been determined [18,109e111].Interpretation
The clinical implications of density change or stability
must be incorporated into the interpretation section of the
report [11,40,95,97,99e101]. This is of greatest importance
for patients on osteoporosis drug therapy, when BMD is
often being used to assist in monitoring drug actions
[8,11,15,35,40,95,98e101,111]. The primary BMD outcome
of interest in this circumstance is the net change in density
from the time that the current drug regimen was initiated
[35,36,40,95,97,99,100]. In general, net stability or a gain in
density is considered positive drug effect, whereas net loss of
density is considered evidence of drug failure [35,36].
Secondary changes in the BMD profile that may differ from
the net change on a drug regimen, such as a change from the
most recent prior study, also need to be considered in the
interpretation [99,101,108]. For serial studies of those
patients on osteoporosis drug therapies, there are similarimplications for the effects of nutritional supplements,
lifestyle changes, and exercise regimens [2,35].
There are insufficient data at this time to define the
relationship between the amount of loss and the resulting
change in fracture risk, so loss of density is not incorporated
into the absolute fracture-risk methodology. The reported
absolute fracture risk should not be altered because of loss in
density. Instead, the implications of density loss should be
discussed in the interpretation of results.Definition
 LSC: least significant change is the amount by which 1
BMD value must differ from another for the difference to
be statistically significant at a 95% level of confidence.Components of a First-time Pediatric BMD ReportPediatric-age recommendations are an addition to the
2005 CAR guidelines. The pediatric population is defined as
individuals younger than age 18 years old. An exception is
made (as described in ‘‘Components of a First-time Adult
BMD Report, Limitations’’) for manufacturer software that
does not provide T-scores between the ages of 18 and
20 years. It is acceptable in this circumstance to provide
Z-scores and to use the pediatric approach to reporting for
these individuals. It should be noted in the report that results
are being evaluated by using a pediatric approach.
The components of a first-time pediatric BMD report are
shown in Appendix e6. Components that are similar to the
content of an adult first-time BMD report include demo-
graphics, machine identification, and limitations [18,19,112].
There are differences with regard to diagnostic category,
BMD data and interpretation, and specific definitions apply
to reporting in this age group [18e20,112,113]. There are no
guidelines on timing of follow-up studies, so a recommended
follow-up date is not mandatory, although may be included at
the discretion of the reporting physician. A pediatric history
sheet is not provided, because there are no mandatory items
incorporated into the report (as in adult absolute risk deter-
mination), but the adult history sheet can be adapted. History
should be collected relevant to the individual pediatric
patient and may include fracture history, medications, and
illnesses [18,20,21,112e128]. Height and weight measure-
ments in younger children require special devices and
procedures [41]. If these are not available, then it is
acceptable in younger children to use values provided by
other medical practitioners. If height or weight data were not
measured directly by the BMD facility, then this should be
indicated in the report.Diagnostic Category
The current standard for reporting the diagnostic category
in the pediatric population is shown in Appendix e3. The
diagnostic category is based on the lowest adjusted Z-score
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either bone mineral content (BMC) or BMD at the discretion
of the reporting physician [18e20,75,112,126]. See
‘‘Components of a First-time Pediatric BMD Report, BMD
Data’’ for clarification of Z-score adjustment. The T-score is
not to be used in pediatric reporting [18,20,75,112,116]. If
either the spine or total body value is not available or is
invalid, then this should be reported as a limitation. Forearm
measurements (one-third or 33% site) may be used if either
the spine or the total body value is not available but only if
a reference population database is available from which
forearm Z-scores can be derived [18e21]. Proximal femur
measurements are not to be used to generate the diagnostic
category in the pediatric population, although it may be
clinically useful to begin measuring hip density in older
adolescents to transition into the adult mode of monitoring
[1,18,19,112,117].BMD Data
Care must be taken in all technical aspects of how
scanning is performed, including adherence to manufacturer
protocols, proper positioning, subregion assignment, bone
tracing, determination of regions of interest, and quality
assurance [18,19,40,58e67]. Results should be reported for
the lumbar spine and total body, including BMC and BMD
for each site [18,20,112e115]. When analysing the lumbar
spine, L1-L4 should be used unless the decision is made to
exclude 1 or 2 vertebrae because of technical artifacts
[1,45,63]. A minimum of 2 vertebrae should be used
[1,45,70,71]. Interpretation should never be based on a single
vertebra [1,45,70,71]. If a report includes graphical repre-
sentation of results, then the graph must present data and
reference curves for the vertebrae actually used in interpre-
tation [1]. Consideration can be given to excluding a partic-
ular vertebra if the Z-score of that vertebra is more than 1
standard deviation greater than the Z-score of the vertebra
with the next highest value [1,63,72]. It is not mandatory that
the high-density vertebra be excluded, but it should be
evaluated for causes of artifact and a decision made as to
whether it should be included in the vertebral analysis. On
some manufacturers’ databases, Z-scores may not be
available if vertebrae are excluded. In this circumstance, it is
appropriate to include L1-L4 to generate a Z-score, but the
interpretation section must address the accuracy of the spine
measurement and the ways in which the Z-score may have
been perturbed by the abnormal vertebrae. For the total body
measurement, the head may be included or excluded when
analysing the scan [20,112,113]. If the head is excluded, then
this should be noted in the report. For adolescent patients
whose weight exceeds the limit of the DXA equipment,
bilateral forearm studies may be done unless 1 side is not
available or is invalid, in which case a single side can be
measured [112,113,118].
For each skeletal site with a valid scan, reported density
results should include absolute BMD (in g/cm2 to 3 decimalplaces), BMD Z-score (to 1 decimal place), and adjusted
BMD Z-score (to 1 decimal place); and BMC (in grams, to
2 decimal places), BMC Z-score (to 1 decimal place), and
adjusted BMC Z-score (to 1 decimal place) [18e
20,112,129]. The Z-score adjustment is done to correct for
relative skeletal size or maturation. There is no consensus at
this time as to the specific adjustment that should be made, so
the nature of the adjustment is at the discretion of the
reporting physician. Adjustment can be based on height,
weight, body mass index, bone area, bone age, pubertal
stage, lean body mass, or a combination of these parameters
[18e20,112,113,126,127,130e134]. The method of adjust-
ment should be noted in the report, and, if a multivariable
method is used, then a published reference should be
provided. The assignment of diagnostic category should
be based on the adjusted Z-scores by using the BMC Z-score,
the BMD Z-score, or the lower of the 2, at the discretion of
the reporting physician. Some manufacturers provide height
or weight corrections as part of the DXA software. For those
manufacturers whose DXA software does not provide such
corrections, an approach to correcting for bone age or height
age is described in Appendix e7 [20,112]. Each method of
correction has limitations and constraints, and these need to
be considered in the interpretation [112e116].
Bone area, corrected bone area, and area Z-scores are not
required but can be included at the discretion of the reporting
physician [18,112,114,126,129]. All Z-scores should be
derived by using a white female reference population data-
base for girls and a white male database for boys. Non-white
reference databases should not be used at this time, although
they may become acceptable in the future when they are
better validated. The reference database and version should
be specified in the report [1,19,20,112,129]. If the reference
database that is used to generate Z-scores is not one provided
by the manufacturer, then a published reference should be
provided. Z-scores may not be available for certain skeletal
sites at young ages and so do not need to be reported.Definitions
Any terminology or abbreviation used in the report should
be defined. An example relevant to the pediatric report:
 Z-score: the number of standard deviations above (þ) or
below (e) the mean density for an individual of that age
and sex.Components of a Follow-up Pediatric BMD ReportThe components of a follow-up pediatric BMD report are
shown in Appendix e8. A follow-up pediatric BMD report
should include all of the components of a first-time pediatric
report. In addition, items specific to follow-up also need to be
described, including changes in density, statistical parame-
ters that relate to measurement error, and aspects of
interpretation that relate to the changes in density.
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When comparing serial assessments, positioning and
subregion assignment must be consistent [135e137]. The
same reference population database should be used for serial
studies whenever possible [112,138]. If the reference
population database must be changed, then this should be
noted in the report. The description of density change should
include the absolute density change (in g/cm2, to 3 decimal
places), percentage change (to 1 decimal place, derived by
using absolute density, not Z-scores), change in Z-score, and
change in adjusted Z-score [18,112,113]. Annualized rates of
change may be reported, but this is optional [114,139]. The
skeletal sites for which changes in density are to be reported
are the lumbar spine (by using whichever vertebrae are
considered valid, with a minimum of 2 vertebrae) and the total
body [112,113,138,139]. If the forearm is being monitored in
lieu of the spine or the total body, then change can be reported
for the one-third or 33% proximal radius [113,114,118]. It
must be recognized that the change profile at the forearm may
not parallel changes at the spine and the total body, and may not
correlate as well with drug responses. This will need to be
addressed in the interpretation section, if applicable.
Changes in density must be reported in relation to: (1) the
first study on file; and (2) the most recent previous study.
Pediatric osteoporosis drug treatment regimens are not well
defined, and, if information is not provided by the referring
physician, then it can be difficult to ascertain the timing of
the BMD study that corresponds to the initiation of a clinical
treatment regimen. It, therefore, is not mandatory at this time
that changes are reported in relation to the initiation of
treatment. This can be provided at the discretion of the
reporting physician if it is thought that an appropriate
comparison study can be defined in relation to treatment.
Statistical significance must be reported for each BMD
skeletal-site comparison and indicate whether the diffe-
rence is considered significant at a 95% level of confi-
dence [103e108,112,140,141]. The manufacturer’s software
determination of statistical significance is not to be used
[1,18,61]. Each facility must determine precision error for each
DXA machine and for each skeletal site (including forearm if
this site is measured by the facility and used for serial moni-
toring) by using the LSC methodology and use this value when
determining statistical significance [18,61,105e108]. It is
permissible to apply results derived from precision testing of
the forearm on 1 side to serial scans done by using the opposite
side of the body. Facilities are encouraged to derive precision
by using pediatric-age subjects, particularly facilities that
perform only pediatric clinical tests. In the absence of data that
prove that precision differs between adults and children,
however, it is acceptable at this time for all facilities to use
precision derived from adult subjects [112]. If precision is
derived by using adult subjects, then this should be noted in the
report. A follow-up pediatric BMD report should state the LSC
in absolute values (g/cm2, to 3 decimal places for BMD; grams,
to 2 decimal places for BMC) for each skeletal site for which
change is reported and for both BMD and BMC [18,112].Whenever possible, the same instrument should be used for
serial studies on an individual patient [1,15,63]. Comparisons
between measurements done on different machines can be
made only if intermachine precision between the 2 devices has
been determined [18,109e111].
There is no accepted methodology at this time for
evaluating statistical significance of Z-score differences at
different time points. The change in Z-score between
comparison BMD studies should be noted. An opinion as to
whether the difference is clinically meaningful should be
incorporated into the interpretation section. It is not
necessary to report changes in either height or weight.
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Please complete this questionnaire while waiting for your
bone mineral density test.
This document will be reviewed with you. A staff member
will measure your height and weight.
Appendix e2
Components of a First-time Adult Bone Mineral Density (BMD) Report




 date of birth
 sex







 facility name and location
Diagnostic Category
Fracture-risk Category (if 50 years of age or older)
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Bone Mineral Density Diagnostic Categories
Patient group Category name T-score value Adjusted Z-score value
Women 50 y or older Normal  e1.0
Osteopenia Between e1 and e2.5
Osteoporosis  e2.5
Women younger than age 50 y Normal > e2.5
Reduced  e2.5
Men Normal > e2.5
Reduced  e2.5
Childrena Normal > e2.0
Reduced  e2.0
a Defined as being younger than age 18 years; adjusted Z-score indicates adjustment for one or more of height, weight, body mass index, bone area, bone age,
pubertal stage, and lean body mass.
Appendix e4
Recommended Timing of Follow-up Bone Mineral Density (BMD) Tests
Expected rate of BMD change Clinical example Timing of follow-up
Very high Moderate-to-high dose glucocorticoids, anabolic agent 6e12 mo
High Osteoporosis drug therapy initiated or changed, low-to-moderate dose glucocorticoids 1e2 y
Moderate Therapy with nutritional supplements or lifestyle improvements 2e3 y
Low Stability documented on nutritional supplements or lifestyle improvements and with no change in
clinical status; drug therapy shown to be effective
3e5 y
Very low Normal results or low fracture risk, and no clinical risks Not indicated
Appendix e5
Components of a Follow-up Adult Bone Mineral Density (BMD) Report




 date of birth
 sex
 provincial health care number or other identifier
 height
 weight





 facility name and location
Diagnostic Category
Fracture-risk Category




 reference database used
Changes in Density
 BMD change
 percentage BMD change
 statistical significance










Components of a First-time Pediatric Bone Mineral Density (BMD) Report
All first pediatric (younger than age 18 years old) BMD reports should include the following components in this
recommended order of presentation:
Demographics
 name
 date of birth
 sex







 facility name and location
Diagnostic Category
BMD Data
 bone mineral content (BMC)
 BMC Z-score
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 adjusted BMC Z-score
 BMD
 BMD Z-score
 adjusted BMD Z-score









Method for Adjusting Z-score for Bone Age or Height Age
Z-score Adjustment for Bone Age
1. Determine Z-score for all scan sites based on chronological age.
2. Perform wrist radiographs and derive bone age.
3. Use point estimate of bone age to determine ‘‘adjusted birthdate’’ for patient.
4. If bone age differs from chronological age by more than 1 year, then change birthdate to ‘‘adjusted birthdate’’ in the dual-
energy x-ray absorptiometry (DXA) program and determine adjusted Z-scores for all scan sites.
5. Report for all scan sites the Z-scores based on chronological age and the bone ageeadjusted Z-scores. If the bone age does
not differ from chronological age by more than 1 year, then this should be noted in the report and a bone ageeadjusted Z-
score need not be reported.
Example:
Male with birthdate: January 10, 2003. DXA scan date July 10, 2010. Chronological age on scan date: 7 years 6 months. Z-
scores derived by using chronological age.
Bone age by wrist radiographs: 5 years 6 months. Adjusted birthdate is assigned as January 10, 2005. Bone ageeadjusted
Z-scores are derived by using bone age.
Report for each skeletal site includes bone mineral density (BMD) (in g/cm2, to 3 decimal places), BMD Z-score (to
1 decimal place), and bone ageeadjusted BMD Z-score (to 1 decimal place); and bone mineral content (BMC) (in grams to
2 decimal places), BMC Z-score (to 1 decimal place), and bone age-adjusted BMC Z-score (to 1 decimal place).
Z-score Adjustment for Height Age
1. Determine Z-score for all scan sites based on chronological age.
2. Determine ‘‘height age’’ by using growth charts for the child’s sex (available at www.cdc.gov/GrowthCharts).
3. Measure height 3 times and use the average value as patient height.
4. By using the patient’s height on the vertical axis of the Centers for Disease Control (CDC) growth chart, locate where this
height line intersects the 50th percentile growth curve. By extrapolating to the horizontal axis, determine the age that
corresponds to the point on the 50th percentile growth curve. This is the patient’s ‘‘height age.’’
5. If the height age differs from the chronological age by more than 1 year, then change birthdate to ‘‘adjusted birthdate’’ in
the DXA program and determine adjusted Z-scores for all scan sites.
6. Report, for all scan sites, the Z-scores based on chronological age and the height ageeadjusted Z-scores. If height age does
not differ from chronological age by more than 1 year, then this should be noted in the report, and a height agee
adjusted Z-score need not be reported.
Example:
Female with birthdate: January 10, 1999. DXA scan date July 10, 2010. Chronological age on scan date: 11 years 6 months.
Z-scores derived by using chronological age.
Height is measured 3 times by using a stadiometer with repositioning between measurements: 134.4 cm, 133.8 cm, 135.3
cm; the average height is 134.5 cm.
On CDC Growth Chart ‘‘Stature-for-age percentiles: girls, 2e0 years,’’ a height of 134.5 cm corresponds to an age of 9
years 3 months at the 50th percentile.
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Adjusted birthdate assigned as April 10, 2001. Height age-adjusted Z-scores are derived by using height age.
Report for each skeletal site includes BMD (in g/cm2, to 3 decimal places), BMD Z-score (to 1 decimal place), and height
age-adjusted BMD Z-score (to 1 decimal place); and BMC (in grams, to 2 decimal places), BMC Z-score (to 1 decimal place),
and height age-adjusted BMC Z-score (to 1 decimal place).
Appendix e8
Components of a Follow-up Pediatric Bone Mineral Density (BMD) Report




 date of birth
 sex







 facility name and location
Diagnostic Category
BMD Data
 bone mineral content (BMC)
 BMC Z-score
 adjusted BMC Z-score
 BMD
 BMD Z-score
 adjusted BMD Z-score
 reference database used
Changes in Density
 BMC change
 percentage BMC change
 change in BMC Z-score
 statistical significance of BMC change
 BMC least significant change (LSC)
 BMD change
 percentage BMD change
 change in BMD Z-score
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